 Equillium Inc NASDAQ: EQ completed an End-of-Phase 1 meeting with the FDA, confirming to advance itolizumab into a single Phase 3 pivotal study in first-line treatment of acute graft-versus-host disease aGVHD patients. The company plans to initiate the Phase 3 study in 4Q of 2021. 